MOESM1 of Spread of multidrug resistance among Ureaplasma serovars, Tunisia
2020-01-24T04:51:39Z (GMT) by
Additional file 1: Table S1. Genes and respective flanking oligonucleotide primers used. Table S2. Epidemiologic characteristics of Ureaplasma spp. strains used. Table S3. In-vitro activity of tetracyclines, fluoroquinolones, and macrolides against 101 human Ureaplasma spp. isolates. Table S4. Distribution of antimicrobial resistance among patients with genital tract infections and infertility. Figure S5. PCR results screening for tet (M) (A) and Int-Tn genes (B) on 2% agarose gel. A. MW: GeneRuler 100 base pairs (bp) DNA Ladder. Lane 1: Negative control. Lane 2–13: Amplicons from the tetracycline-resistant Ureaplasma spp. clinical isolates. Lane 14–15: Amplicons from U. parvum ATCC 27815 and U. urealyticum ATCC 27618. Lane 16–21: Amplicons from tetracycline-sensitive Ureaplasma spp. clinical isolates. The tet (M) expected gene product is 397 bp based on the primers used. B. MW: GeneRuler 100 (bp) DNA Ladder. Lane 1: Negative control. Lane 2: Amplicon from a tetracycline-sensitive Ureaplasma spp. clinical isolate. Lane 3–12: Amplicons from tetracycline-resistant Ureaplasma spp. clinical isolates. The Int-Tn expected gene product is 579 bp based on the primers used. (338 KB).